Back | Next |
home / stock / okyo / okyo message board
Subject | By | Source | When |
---|---|---|---|
$OKYO What do you make of this? | mfayman | investorshub | 09/24/2023 2:51:58 PM |
The gaining last up | Count Crypto | investorshub | 09/24/2023 11:55:48 AM |
where is the squeeze? | Count Crypto | investorshub | 09/24/2023 10:47:24 AM |
$OKYO Good news recently, we should start to see this one move | Sirpeter | investorshub | 09/24/2023 10:35:06 AM |
short squeeze | mfayman | investorshub | 09/24/2023 9:20:27 AM |
$OKYO MomentumIts gaining | mfayman | investorshub | 09/24/2023 8:00:42 AM |
here we go bulls news is here | Ryguy008 | investorshub | 09/24/2023 6:31:53 AM |
Anyone hear anything lately? Want to see this one go | glenn1919 | investorshub | 09/24/2023 6:26:22 AM |
Price gaining last trade up | mfayman | investorshub | 09/24/2023 5:41:07 AM |
Price trading up | Count Crypto | investorshub | 09/24/2023 5:39:53 AM |
$OKYO oh yeah news for the day | mfayman | investorshub | 09/24/2023 5:08:28 AM |
$OKYO news out | Count Crypto | investorshub | 09/24/2023 4:35:27 AM |
$OKYO what do you make of this data? | mfayman | investorshub | 09/24/2023 1:54:59 AM |
$OKYO MomentumIts now last trade up | Boris the Spider | investorshub | 09/23/2023 11:27:43 PM |
$OKYO Good news recently, we should start to see this one move | Anita Dump | investorshub | 09/23/2023 9:40:17 PM |
$OKYO Time for a bounce? | Pisd | investorshub | 09/23/2023 8:30:17 PM |
is it bear time? Or do we go bull? | Ryguy008 | investorshub | 09/23/2023 6:45:38 PM |
$OKYO Time for a bounce? | mfayman | investorshub | 09/23/2023 6:11:31 PM |
$OKYO news out | Anita Dump | investorshub | 09/23/2023 5:46:59 PM |
$OKYO is it bear time? Or do we go bull? | glenn1919 | investorshub | 09/23/2023 4:56:37 PM |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...